Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab plus Pyrotinib and Capecitabine in HER2+ MBC
NCT06015100Phase 2Unknown
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inetetamab, pyrotinib in HER2-positive metastatic breast cancer. Status: unknown.
02
Drugs
inetetamabpyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT06015100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015100.